Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunotherapy in ocular diseases].

M Mochizuki1

  • 1Department of Ophthalmology, Kurume University School of Medicine.

Nippon Ganka Gakkai Zasshi
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Immunophilin ligands like FK506 and cyclosporine show promise in treating immune-mediated ocular disorders, including uveitis and corneal transplant rejection. Combination therapies and FK506 demonstrate significant therapeutic effects with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spontaneous production of various cytokines except IL-4 from CD4+ T cells in the affected organs of sarcoidosis patients.

Clinical and experimental immunology·1995
Same author

Inducible expression of a gene encoding an L41 ribosomal protein responsible for the cycloheximide-resistant phenotype in the yeast Candida maltosa.

Journal of bacteriology·1995
Same author

Intracranial meningioma masquerading as a primary pleuropulmonary tumor.

Pathology international·1995
Same author

Mitochondrial encephalomyopathy with A to G transition of mitochondrial transfer RNA(Leu(UUR)) 3,243 presenting hypertrophic cardiomyopathy.

Internal medicine (Tokyo, Japan)·1995
Same author

[Differential patterns of the number and proportion of blood leukocytes following endurance exercise of moderate, strenuous and severe conditions].

Nihon eiseigaku zasshi. Japanese journal of hygiene·1995
Same author

Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis.

Experimental eye research·1995
Same journal

Guidance of Medical Care for Familial Exudative Vitreoretinopathy：Research on Rare and Intractable Diseases, Health and Labour Sciences Research Grants.

Nippon Ganka Gakkai zasshi·2018
Same journal

Steroid Resistant Vogt-Koyanagi-Harada Disease Treated Effectively with Cyclosporine.

Nippon Ganka Gakkai zasshi·2018
Same journal

The Effect of Low-dose Cyclosporine (100 mg Once Daily) for Chronic Vogt-Koyanagi-Harada Disease.

Nippon Ganka Gakkai zasshi·2018
Same journal

Clinical Classification of Degree of Deficiency in Color Defectiveness: Simulations by Changing the Total Number of Caps or Saturation of Farnsworth Dichotomous Test D-15.

Nippon Ganka Gakkai zasshi·2018
Same journal

Accelerated Epithelial Proliferation in a Rabbit Model of Bullous Keratopathy.

Nippon Ganka Gakkai zasshi·2018
Same journal

Non-infectious Uveitis and Immunosuppressants：Where We Stand and What the Future Holds.

Nippon Ganka Gakkai zasshi·2018
See all related articles

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Immune-mediated ocular disorders such as uveitis and corneal transplant rejection pose significant clinical challenges.
  • Immunophilin ligands, including FK506 and cyclosporine, are potent immunosuppressants with potential therapeutic applications in these conditions.

Observation:

  • In an animal model of uveitis (EAU), immunophilin ligands demonstrated intense and prolonged suppression of disease development, therapeutic effects post-onset, selective immune response modulation, and induction of tolerance.
  • Combination therapy with low-dose cyclosporine and bucillamine, or low-dose FK506 and dexamethasone, enhanced therapeutic effects in EAU models compared to monotherapy.
  • Clinical trials in refractory uveitis showed FK506 improved outcomes in 60% of cases, including those resistant to cyclosporine, with significant reduction in uveitis attacks in Behçet's disease patients.

Related Experiment Videos

Findings:

  • FK506 therapy demonstrated significant efficacy in treating posterior uveitis, with a notable success rate in patients previously unresponsive to cyclosporine.
  • Systemic and topical administration of FK506, as well as systemic cyclosporine, effectively suppressed allograft rejection in rat corneal transplantation models.
  • FK506 exhibited a correlation between trough blood levels, therapeutic efficacy, and adverse side effects, suggesting a therapeutic window between 15-25 ng/ml.

Implications:

  • Immunophilin ligands, particularly FK506, represent a valuable therapeutic option for managing severe immune-mediated ocular disorders.
  • Combination immunotherapy strategies may offer enhanced efficacy and reduced side effects in treating complex ocular inflammatory conditions.
  • Further research into FK506 dosing and monitoring is warranted to optimize its use in clinical ophthalmology.